BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CV&Met Disease Analysis: Osteoporosis

March 25, 2021

The osteoporosis market is set for moderate growth during the forecast period, primarily driven by growth of Amgen’s Prolia in the US, Japan, and EU until its loss of patent exclusivity allows biosimilars to enter the market.

Although the uptake of anabolic therapies will increase in terms of volumes, the value of this class is expected to decrease, due primarily to Forteo’s loss of exclusivity coupled with the arrival of two cheaper anabolic therapies in the US. Tymlos is expected to take significant market share from Forteo due to its competitive efficacy profile. Evenity’s growth will also contribute to the reduction in volume of Forteo, primarily due to a favorable efficacy profile and convenient monthly dosing over 12 months. However, while physicians may have found a way to mitigate the black box warning for increased CV risk (particularly by excluding patients with prior myocardial infarction, stroke, or CV risk factors), this will remain a growth barrier for Evenity.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Osteoporosis / Osteopenia
Back to the top Back to the top